Bayer warns that Nexavar patent may be vulnerable to revocation
This article was originally published in Scrip
Bayer has claimed that its patent for the anticancer Nexavar (sorafenib tosylate) could become ''vulnerable'' for revocation in India, since Natco Pharma, the compulsory licence holder, may not be able to meet the ''reasonable requirements'' of the public as envisaged in the landmark compulsory licensing order in March this year (www.scripintelligence.com, 12 March, 2012).
You may also be interested in...
Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.